1. Cell Cycle/DNA Damage
    Epigenetics
  2. PARP

E7449 

Cat. No.: HY-12418 Purity: 99.09%
Data Sheet SDS Handling Instructions

E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2; enhances the efficacy of radiotherapy and chemotherapy and has potent single agent anticancer activity in BRCA-deficient tumors.

For research use only. We do not sell to patients.
E7449 Chemical Structure

E7449 Chemical Structure

CAS No. : 1140964-99-3

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $132 In-stock
5 mg $120 In-stock
10 mg $210 In-stock
25 mg $420 In-stock
50 mg $750 In-stock
100 mg $1350 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2; enhances the efficacy of radiotherapy and chemotherapy and has potent single agent anticancer activity in BRCA-deficient tumors. IC50 value: Target: PARP1/2 inhibitor E7449 is an orally bioavailable, potent, small molecule inhibitor of Poly(ADP-ribose) Polymerase (PARP)1 and PARP2. E7449 potently inhibits PARP1 and PARP2 in a cell-free assay and potentiates the cytotoxicity of both radiotherapy and chemotherapy. The cytotoxic effect of radiotherapy was enhanced by E7449 in clonogenic survival assays. The anti-tumor activity of the alkylating agent temozolomide was potentiated by E7449 in a dose responsive manner in vivo in the B16-F10 melanoma isograft mouse model. Daily dosing of E7449 as a single agent significantly inhibited tumor growth in a genetically engineered BRCA1 null mouse ovarian xenograft model. In the BRCA1 mutant human breast cancer cell line MDA-MB-436, E7449 significantly inhibited proliferation in a long term growth inhibition assay in vitro. Oral administration of E7449 once daily potently inhibited tumor growth in the MDA-MB-436 xenograft model with no toxicity observed. A dose responsive pharmacodynamic effect on PARP activity was demonstrated in MDA-MB-436 tumor tissue following administration of a single E7449 dose. The decrease in PARP activity was sustained over several hours. The ability of E7449 to inhibit PARP activity in tumor tissue was further investigated in the H460 xenograft model. Following single oral administration of various E7449 dosages, inhibition of PARP activity in tumor tissue was determined over time. Studies revealed that PARP is inhibited by E7449 in a time and dose dependent manner with lower doses resulting in transient inhibition and higher doses causing more complete and sustained PARP inhibition. Conclusion: E7449 is a potent and selective PARP1 and PARP2 inhibitor with potent anti-tumor activity in BRCA-deficient in vivo models. It also potentiates the activity of radiotherapy and chemotherapy pre-clinically. Evaluation of E7449 in a Phase 1 study will be initiated soon.

Clinical Trial
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 3.1512 mL 15.7560 mL 31.5119 mL
5 mM 0.6302 mL 3.1512 mL 6.3024 mL
10 mM 0.3151 mL 1.5756 mL 3.1512 mL
Please refer to the solubility information to select the appropriate solvent.
References
Molecular Weight

317.34

Formula

C₁₈H₁₅N₅O

CAS No.

1140964-99-3

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: < 6.96 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
E7449
Cat. No.:
HY-12418
Quantity: